Cardiomyopathy is a leading cause of heart failure in children, and there are currently no effective treatments. Could emerging therapies that successfully target the root cause of the condition in adults also work well in children? That was the question Dr....
In the realm of cardiac health, an exciting new study has cast light on the intricate details of our hearts, revealing significant differences between the left and right ventricles' fibroblasts. This research, conducted by a team of dedicated scientists from the...
For children diagnosed with complex heart conditions like hypertrophic cardiomyopathy (HCM), the diagnosis can be frightening for families and challenging for healthcare providers since the trajectory of the condition is often uncertain. As a leading cause of sudden...
An innovative cardiovascular start-up, HDAX Therapeutics, is the latest company to win $250,000 in funding following another year of the Ted Rogers Centre for Heart Research’s Entrepreneurship for Cardiovascular Health Opportunities (ECHO) program. The ECHO program...
Several members of the Ted Rogers Centre for Heart Research (TRCHR) participated in Vascular 2023, a five-day conference held in Montreal from October 25-29. The conference is a hallmark event organized by several Canadian specialist and research organizations,...
Researchers at the Ted Rogers Centre for Heart Research have developed an innovative approach to better understanding the complex signaling mechanisms underlying heart failure. A recent publication in the Proceedings of the National Academy of Sciences (PNAS) offers...
Program Overview
Cardiovascular disease is a global health problem with no geographic, gender, or socio-economic boundaries. Despite the tremendous advances in cardiac care made recently, including drugs, devices, and diagnostic innovations, many patients continue to die from heart disease or live with significant morbidity.
Challenges for the next decade include health promotion and disease prevention, obesity and diabetes, and acute heart failure and cardiorenal disease. We must broaden our scope of intervention to emphasize and extend preventive strategies, and translate our innovations into affirmative actions through carefully designed health policy strategies.
Artificial intelligence, along with genomic and proteomic biomarkers, promise to improve early detection and risk stratification, leading to a more personalized approach to cardiovascular medicine.